Main content

Mosaiques diagnostics GmbH

Further Information :



General Description
Over the years, Mosaiques has heavily invested R&D and has developed a unique technology on the basis of clinical proteome analysis, enabling the early and differential detection of renal, cardiovascular, and urogenital diseases. In close collaboration with several academic Institutes in Germany and abroad, Mosaiques is currently developing diagnostic tests for additional indications, such as Alzheimer´s disease, pancreatic cancer, and nephrotoxic effects of drugs. Diagnosis is accomplished by highly specific patterns of multiple simultaneously detected biomarkers (proteins/polypeptides) from patient samples obtained in a risk-free and painless procedure. Mosaiques state of the art research in biostatistics/bioinformatics has made possible to efficiently analyze large amounts of data within minutes. This vast wealth of information is expected to facilitate accurate diagnosis of diseases and enable effective therapy prior to serious organ damage.

Key Personnel


Leif Flühe (PhD) studied chemistry at the Philipps-Universität Marburg, Germany, and the Heriot-Watt University Edinburgh , Scotland from 2005 to 2010. He received his Diploma in Chemistry from the Philipps-Universität Marburg, Germany, in 2010. Afterwards he worked on his PhD thesis in the field of radical SAM enzyme based thioether bond formation at the work group of Prof. Dr. Marahiel (Philipps-Universität Marburg) from 2011 to 2013. During his thesis he published several papers concerning the characterization of a new radical based mechanism not known in nature before. Since September 2013 he holds a position at the mosaiques diagnostics GmbH, Hannover, as head of urologic biomarker research.


Harald Mischak (PhD) received his PhD from the Technical University of Vienna, Austria, in 1986. After postdoctoral work at the University of Vienna, he was a Fogarty Fellow at the NIH, USA. He continued as Group Leader at the GSF, Munich, Germany from 1993-1998. After one year at the NIDDK, NIH, he took up a position at the Medical School of Hannover in 1999, and founded Mosaiques diagnostics in 2002. Today, he is director of Mosaiques diagnostics and professor of proteomics and Systems Medicine at the University of Glasgow, and a worldwide leading authority in clinical proteome analysis, with more than 200 papers published in peer reviewed journals which have been cited over 13000 times (h-factor 61), and more than 100 patents filed.